{"id":"teriparatide-and-alendronate","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Arthralgia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Gastrointestinal upset (alendronate component)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Teriparatide activates PTH1 receptors on osteoblasts to increase bone formation and mineral density. Alendronate inhibits osteoclast-mediated bone resorption by blocking farnesyl pyrophosphate synthase in the mevalonate pathway. Together, they aim to maximize net bone gain in osteoporosis patients, though sequential rather than concurrent dosing is typically recommended to avoid antagonism.","oneSentence":"This combination pairs teriparatide (a PTH analog that stimulates bone formation) with alendronate (a bisphosphonate that inhibits bone resorption) to address osteoporosis through complementary anabolic and anti-catabolic pathways.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:11:48.480Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Osteoporosis in postmenopausal women and men at high risk of fracture"}]},"trialDetails":[{"nctId":"NCT07242612","phase":"NA","title":"Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis","status":"RECRUITING","sponsor":"Khyber Medical University Peshawar","startDate":"2025-10-01","conditions":"Osteoporosis, Osteoporosis, Postmenopausal","enrollment":40},{"nctId":"NCT07028320","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women With Osteoporosis at High Fracture Risk","status":"COMPLETED","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","startDate":"2021-12-03","conditions":"Postmenopausal Women With Osteoporosis","enrollment":493},{"nctId":"NCT05151484","phase":"PHASE4","title":"Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover","status":"RECRUITING","sponsor":"Madhumathi Rao","startDate":"2022-03-21","conditions":"Age-Related Osteoporosis","enrollment":60},{"nctId":"NCT06264609","phase":"PHASE4","title":"Precision Medicine Approach for Osteoporosis - Follow Up Study","status":"ENROLLING_BY_INVITATION","sponsor":"Paul F Netzel","startDate":"2024-02-01","conditions":"Osteoporosis","enrollment":40},{"nctId":"NCT05366621","phase":"","title":"Post-fracture Medication and Mortality","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2020-11-01","conditions":"Osteoporosis, Osteoporosis Fracture, Drug Therapy","enrollment":216155},{"nctId":"NCT02195895","phase":"PHASE2","title":"Effect of Alendronate on Bone in People With Chronic Spinal Cord Injury (SCI) Previously Treated With Teriparatide","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2014-04","conditions":"Spinal Cord Injury, Bone Loss, Osteoporosis","enrollment":17},{"nctId":"NCT02440581","phase":"NA","title":"Renal Osteodystrophy: An Individual Management Approach","status":"COMPLETED","sponsor":"Hartmut Malluche, MD","startDate":"2015-07-01","conditions":"Kidney Failure, Chronic","enrollment":141},{"nctId":"NCT00896532","phase":"PHASE2","title":"Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-06-03","conditions":"Low Bone Mineral Density, Postmenopausal Osteoporosis","enrollment":419},{"nctId":"NCT01656629","phase":"NA","title":"Stem Cell Recruitment in Osteoporosis Therapy","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2012-08","conditions":"Low Bone Density","enrollment":55},{"nctId":"NCT03692143","phase":"","title":"Comparation of Treatment Strategies for OVF: Teriparatide Injection and PVP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2017-01-01","conditions":"Osteoporosis, Postmenopausal, Vertebral Fracture, Quality of Life","enrollment":90},{"nctId":"NCT00471237","phase":"PHASE2","title":"A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis.","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2007-05-14","conditions":"Osteoporosis","enrollment":564},{"nctId":"NCT00668941","phase":"PHASE2","title":"Cyclic Versus Daily Teriparatide on Bone Mass","status":"UNKNOWN","sponsor":"Helen Hayes Hospital","startDate":"2005-09","conditions":"Osteoporosis","enrollment":140},{"nctId":"NCT01750086","phase":"PHASE4","title":"Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2013-01","conditions":"Postmenopausal Osteoporosis","enrollment":27},{"nctId":"NCT02166437","phase":"","title":"Clinical Results of Bisphosphonate and Denosumab Therapy Following Teriparatide Therapy for Japanese","status":"UNKNOWN","sponsor":"Tomidahama Hospital","startDate":"2013-11","conditions":"Osteoporosis","enrollment":500},{"nctId":"NCT00005006","phase":"PHASE2","title":"Parathyroid Hormone (PTH) With Alendronate for Osteoporosis","status":"COMPLETED","sponsor":"Helen Hayes Hospital","startDate":"1987-09","conditions":"Osteoporosis","enrollment":140},{"nctId":"NCT02416271","phase":"PHASE4","title":"The Forteo Alendronate Comparator Trial","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2001-04","conditions":"Osteoporosis","enrollment":203},{"nctId":"NCT00000400","phase":"PHASE2","title":"Alendronate and/or Parathyroid Hormone for Osteoporosis","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"1999-08","conditions":"Osteoporosis","enrollment":176},{"nctId":"NCT00891553","phase":"","title":"CR9112792, a Follow-up of Study CR9108963","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-03","conditions":"Osteoporosis","enrollment":171},{"nctId":"NCT01535027","phase":"PHASE4","title":"Combined Administration of Teripapartide and Antiresorptive Agents in Postmenopausal Osteoporosis","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2006-03","conditions":"Osteoporosis","enrollment":125},{"nctId":"NCT00051558","phase":"PHASE3","title":"Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2002-11","conditions":"Osteoporosis","enrollment":428},{"nctId":"NCT00079924","phase":"PHASE4","title":"Effects of Teriparatide in Postmenopausal Women With Osteoporosis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2004-11","conditions":"Postmenopausal Osteoporosis","enrollment":200},{"nctId":"NCT00191893","phase":"PHASE3","title":"Bone Effects of Teriparatide Following Alendronate","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2003-09","conditions":"Osteoporosis","enrollment":66}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":463,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Forteo","Fosamax"],"phase":"marketed","status":"active","brandName":"teriparatide and alendronate","genericName":"teriparatide and alendronate","companyName":"Medical University of Vienna","companyId":"medical-university-of-vienna","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination pairs teriparatide (a PTH analog that stimulates bone formation) with alendronate (a bisphosphonate that inhibits bone resorption) to address osteoporosis through complementary anabolic and anti-catabolic pathways. Used for Osteoporosis in postmenopausal women and men at high risk of fracture.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}